Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019

References

• Gershon AA, Breuer J, Cohen JI, Cohrs RJ, Gershon MD, Gilden D, Grose C, Hambleton S, Kennedy PG, Oxman MN, et al. Varicella zoster virus infection. Nat Rev Dis Primers. 2015;1:15016. doi:10.1038/nrdp.2015.16.
   PubMed Web of Science ®Google Scholar
• Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin. 2008;26:675–97. doi:10.1016/j.ncl.2008.03.011.
   PubMed Web of Science ®Google Scholar
• Cohen JI. Clinical practice: herpes zoster. New England J Med. 2013;369:255–63. doi:10.1056/NEJMcp1302674.
   PubMed Web of Science ®Google Scholar
• Oxman MN. Herpes zoster pathogenesis and cell-mediated immunity and immunosenescence. J Am Osteopath Assoc. 2009;109:S13–S17.
   PubMed Web of Science ®Google Scholar
• Patterson BJ, Rausch DA, Irwin DE, Liang M, Yan S, Yawn BP. Analysis of vascular event risk after herpes zoster from 2007 to 2014 US insurance claims data. Mayo Clin Proc. 2019;94:763–75. doi:10.1016/j.mayocp.2018.12.025.
   PubMed Web of Science ®Google Scholar
• Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82:1341–49. doi:10.4065/82.11.1341.
   PubMed Web of Science ®Google Scholar
• Drolet M, Brisson M, Schmader KE, Levin MJ, Johnson R, Oxman MN, Patrick D, Blanchette C, Mansi JA. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. CMAJ. 2010;182:1731–36. doi:10.1503/cmaj.091711.
   PubMed Web of Science ®Google Scholar
• Curran D, Oostvogels L, Heineman T, Matthews S, McElhaney J, McNeil S, Diez-Domingo J, Lal H, Andrews C, Athan E, et al. Quality of life impact of an adjuvanted recombinant zoster vaccine in adults aged 50 years and older. J Gerontol A Biol Sci Med Sci. 2019;74:1231–38. doi:10.1093/gerona/gly150.
   PubMed Web of Science ®Google Scholar
• Chen N, Li Q, Yang J, Zhou M, Zhou D, He L. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2014;2:CD006866. doi:10.1002/14651858.CD006866.pub3.
   PubMed Web of Science ®Google Scholar
• Argoff CE, Katz N, Backonja M. Treatment of postherpetic neuralgia: a review of therapeutic options. J Pain Symptom Manage. 2004;28:396–411. doi:10.1016/j.jpainsymman.2004.01.014.
   PubMed Web of Science ®Google Scholar
• Gater A, Abetz-Webb L, Carroll S, Mannan A, Serpell M, Johnson R. Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study. BMC Infect Dis. 2014;14:402. doi:10.1186/1471-2334-14-402.
   PubMed Web of Science ®Google Scholar
• Oster G, Harding G, Dukes E, Edelsberg J, Cleary PD. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain. 2005;6:356–63. doi:10.1016/j.jpain.2005.01.359.
   PubMed Web of Science ®Google Scholar
• Chlibek R, Pauksens K, Rombo L, van Rijckevorsel G, Richardus JH, Plassmann G, Schwarz TF, Catteau G, Lal H, Heineman TC. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2016;34:863–68. doi:10.1016/j.vaccine.2015.09.073.
   PubMed Web of Science ®Google Scholar
• van der Heiden M, de Rond LGH, van Zelm MC, Berbers GAM, Boots AMH, Buisman AM. Age-dependent pre-vaccination immunity affects the immunogenicity of varicella zoster vaccination in middle-aged adults. Front Immunol. 2018;9:46. doi:10.3389/fimmu.2018.00046.
   PubMed Web of Science ®Google Scholar
• Dooling KL, Guo A, Patel M, Lee GM, Moore K, Belongia EA, Harpaz R. Recommendations of the advisory committee on immunization practices for use of Herpes Zoster vaccines. Morb Mortal Wkly Rep. 2018;67:103–08. doi:10.15585/mmwr.mm6703a5.
   PubMed Web of Science ®Google Scholar
• Hastie A, Catteau G, Enemuo A, Mrkvan T, Salaun B, Volpe S, Smetana J, Rombo L, Schwarz T, Pauksens K, et al. Immunogenicity of the adjuvanted recombinant zoster vaccine: persistence and anamnestic response to additional doses administered 10 years after primary vaccination. J Infect Dis. 2020:jiaa300. doi:10.1093/infdis/jiaa300.
   Web of Science ®Google Scholar
• Lal H, Poder A, Campora L, Geeraerts B, Oostvogels L, Vanden Abeele C, Heineman TC. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: results of a phase III, randomized, open-label, multicenter study. Vaccine. 2018;36:148–54. doi:10.1016/j.vaccine.2017.11.019.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–96. doi:10.1056/NEJMoa1501184.
   PubMed Web of Science ®Google Scholar
• Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Diez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, et al. Efficacy of the Herpes Zoster subunit vaccine in adults 70 years of age or older. N Engl J Med. 2016;375:1019–32. doi:10.1056/NEJMoa1603800.
   PubMed Web of Science ®Google Scholar
• Curran D, Van Oorschot D, Varghese L, Oostvogels L, Mrkvan T, Colindres R, et al. Assessment of the potential public health impact of Herpes Zoster vaccination in Germany. Hum Vaccin Immunother 2017; 13:2213–2221.
   PubMed Web of Science ®Google Scholar
• Curran D, Patterson B, Varghese L, Van Oorschot D, Buck P, Carrico J, et al. Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States. Vaccine 2018; 36:5037–5045.
   Google Scholar
• Le P, Rothberg MB. Cost-effectiveness of the adjuvanted Herpes Zoster subunit vaccine in older adults. JAMA Intern Med. 2018;178:248–258. doi:10.1001/jamainternmed.2017.7431.
   PubMed Web of Science ®Google Scholar
• Dooling KL, HZ Work Group Liaison. Herpes zoster vaccines: update. ACIP meeting Herpes Zoster Vaccine; 2019.
   Google Scholar
• McGirr A, Bourgoin T, Wortzman M, Millson B, McNeil S. An early look at the second dose completion of the recombinant zoster vaccine (RZV) in Canadian adults – a retrospective analysis. Canadian Immunization Research Network; 2019.
   Google Scholar
• Ghaswalla PK, Patterson BJ, Cheng WY, Duchesneau E, Macheca M, Duh MS. Hepatitis A, B, and A/B vaccination series completion among US adults: a claims-based analysis. Hum Vaccin Immunother. 2018;14:2780–85. doi:10.1080/21645515.2018.1489189.
   PubMed Web of Science ®Google Scholar
• Nelson JC, Bittner RC, Bounds L, Zhao S, Baggs J, Donahue JG, et al. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009;99(Suppl 2):S389–97.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Recommended adult immunization schedule for ages 19 years or older, United States, 2020. CDC, ed. 2020.
   Google Scholar
• Johnson DR, Nichol KL, Lipczynski K. Barriers to adult immunization. Am J Med. 2008;121:S28–S35. doi:10.1016/j.amjmed.2008.05.005.
   PubMed Web of Science ®Google Scholar
• Colindres R, Wascotte V, Brecx A, Clarke C, Hervé C, Kim JH, Levin MJ, Oostvogels L, Zahaf T, Schuind A, et al. Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. Hum Vaccin Immunother. 2020:1–6.
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Grupping K, Matthews S, Butuk D, Chen M, et al. The Impact of reactogenicity after the first dose of recombinant zoster vaccine on the physical functioning and quality of life of older adults: an open-label, Phase III Trial. J Gerontol Ser A Biol Sci Med Sci. 2019;74:1217–24.
   PubMed Web of Science ®Google Scholar
• McGee P. Uptake of herpes zoster vaccine linked to supply. In: Internist A, ed. Infectious Disease; 2019.
   Google Scholar
• Williams WW, Lu PJ, O’Halloran A, O’Halloran A, Bridges CB, Kim DK, et al. Vaccination coverage among adults, excluding influenza vaccination - United States, 2013. Morb Mortal Wkly Rep. 2015;64:95–102.
   PubMed Web of Science ®Google Scholar